# Abbott Announces $22.5B Acquisition of Exact Sciences to Expand Cancer Diagnostics

> ma · REPORTED · 2025-11-01

Abbott Laboratories announced the acquisition of Exact Sciences in late November 2025, valued at approximately $22.5 billion, in a strategic move to expand into cancer diagnostics and capitalize on growing demand for early cancer detection and personalized treatment solutions.

About Abbott Laboratories: Exact Sciences is a molecular diagnostics company best known for Cologuard, an FDA-approved non-invasive colorectal cancer screening test, as well as a portfolio of oncology liquid biopsy and precision medicine diagnostics.

- Company: Abbott Laboratories
- Sector: oncology
- Primary source: https://practiceguides.chambers.com/practice-guides/healthcare-ma-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.